These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12460830)

  • 41. Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks.
    Onat A; Can G; Ayhan E; Kaya Z; Hergenç G
    Metabolism; 2009 Oct; 58(10):1393-9. PubMed ID: 19570555
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidemiologic aspects of lipid abnormalities.
    Criqui MH; Golomb BA
    Am J Med; 1998 Jul; 105(1A):48S-57S. PubMed ID: 9707268
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.
    Onat A; Hergenç G; Sansoy V; Fobker M; Ceyhan K; Toprak S; Assmann G
    Atherosclerosis; 2003 May; 168(1):81-9. PubMed ID: 12732390
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elevated hepatic lipase activity and low levels of high density lipoprotein in a normotriglyceridemic, nonobese Turkish population.
    Bersot TP; Vega GL; Grundy SM; Palaoglu KE; Atagündüz P; Ozbayrakçi S; Gökdemir O; Mahley RW
    J Lipid Res; 1999 Mar; 40(3):432-8. PubMed ID: 10064731
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study.
    Wilson PW; Myers RH; Larson MG; Ordovas JM; Wolf PA; Schaefer EJ
    JAMA; 1994 Dec; 272(21):1666-71. PubMed ID: 7966894
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
    Manninen V; Tenkanen L; Koskinen P; Huttunen JK; Mänttäri M; Heinonen OP; Frick MH
    Circulation; 1992 Jan; 85(1):37-45. PubMed ID: 1728471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipids and cardiovascular disease: do the findings and therapy apply equally to men and women?
    LaRosa JC
    Womens Health Issues; 1992; 2(2):102-11; discussion 111-3. PubMed ID: 1617306
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low levels of high density lipoprotein cholesterol in Turkish children: an important risk factor.
    Işcan A; Yiğitoğlu MR; Vurgun N; Uyanik BS; Akyildiz M
    Acta Paediatr Jpn; 1998 Feb; 40(1):41-6. PubMed ID: 9583199
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coronary risk and dyslipidemia in type 2 diabetic patients.
    Udawat H; Goyal RK; Maheshwari S
    J Assoc Physicians India; 2001 Oct; 49():970-3. PubMed ID: 11848328
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cholesterol and coronary events. The current thinking.
    Jones PH
    Postgrad Med; 2003 Apr; 113(4 Suppl):5-14. PubMed ID: 19667618
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A review of the treatment guidelines on the management of low levels of high-density lipoprotein cholesterol.
    Devroey D; Vantomme K; Betz W; Vandevoorde J; Kartounian J
    Cardiology; 2004; 102(2):61-6. PubMed ID: 15103174
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
    Ballantyne CM; Raichlen JS; Cain VA
    J Am Coll Cardiol; 2008 Aug; 52(8):626-32. PubMed ID: 18702965
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population.
    Wang TD; Chen WJ; Chien KL; Seh-Yi Su SS; Hsu HC; Chen MF; Liau CS; Lee YT
    Am J Cardiol; 2001 Oct; 88(7):737-43. PubMed ID: 11589839
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The triglyceride-high-density lipoprotein axis: an important target of therapy?
    Szapary PO; Rader DJ
    Am Heart J; 2004 Aug; 148(2):211-21. PubMed ID: 15308990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.
    Ballantyne CM; Olsson AG; Cook TJ; Mercuri MF; Pedersen TR; Kjekshus J
    Circulation; 2001 Dec; 104(25):3046-51. PubMed ID: 11748098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The pattern of dyslipidemia among urban African-Americans with type 2 diabetes.
    Cook CB; Erdman DM; Ryan GJ; Greenlund KJ; Giles WH; Gallina DL; El-Kebbi IM; Ziemer DC; Ernst KL; Dunbar VG; Phillips LS
    Diabetes Care; 2000 Mar; 23(3):319-24. PubMed ID: 10868858
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Decreased Serum Lipid Levels and Ratios Correlate with Low Prevalence of Coronary Heart Disease in Patients with Parkinson's Disease.
    Bao M; Hu R; Chen Y; Wang N; Xue H; He J; Jin J; Kong W; Ke G; Xue Q
    Clin Lab; 2018 Sep; 64(9):1413-1419. PubMed ID: 30274018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of coronary heart disease is associated with triglycerides and high-density lipoprotein cholesterol in women and non-high-density lipoprotein cholesterol in men.
    Abdel-Maksoud MF; Eckel RH; Hamman RF; Hokanson JE
    J Clin Lipidol; 2012; 6(4):374-81. PubMed ID: 22836075
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in lipid measures and incident coronary heart disease: Tehran Lipid & Glucose Study.
    Nejat A; Mirbolouk M; Mohebi R; Hasheminia M; Tohidi M; Saadat N; Azizi F; Hadaegh F
    Clin Biochem; 2014 Sep; 47(13-14):1239-44. PubMed ID: 24657509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.